Arylsulfamates inhibit colonic Bacteroidota growth through a sulfatase-independent mechanism

Proceedings of the National Academy of Sciences, Volume 122, Issue 28, July 2025. <br/>SignificanceArylsulfamates are currently the only effective class of sulfatase inhibitors available and offer a potential strategy to treat inflammatory bowel disease (IBD) driven by gut microbiota carbohydrate sulfatases. Although arylsulfamates inhibit …